Uterine leiomyomata (UL), the most common neoplasm in reproductive-age women, are classified into distinct genetic subgroups based on recurrent chromosome abnormalities. To develop a molecular signature of UL with t(12;14)(q14-q15;q23-q24), we took advantage of the multiple UL arising as independent clonal lesions within a single uterus. We compared genome-wide expression levels of t(12;14) UL to non-t(12;14) UL from each of nine women in a paired analysis, with each sample weighted for the percentage of t(12;14) cells to adjust for mosaicism with normal cells. This resulted in a transcriptional profile that confirmed HMGA2, known to be overexpressed in t(12;14) UL, as the most significantly altered gene. Pathway analysis of the differentially expressed genes showed significant association with cell proliferation, particularly G1/S checkpoint regulation. This is consistent with the known larger size of t(12;14) UL relative to karyotypically normal UL or to UL in the deletion 7q22 subgroup. Unsupervised hierarchical clustering demonstrated that patient variability is relatively dominant to the distinction of t(12;14) UL compared with non-t(12;14) UL or of t(12;14) UL compared with del(7q) UL. The paired design we employed is therefore important to produce an accurate t(12;14) UL-specific gene list by removing the confounding effects of genotype and environment. Interestingly, myometrium not only clustered away from the tumors, but generally separated based on associated t(12;14) versus del(7q) status. Nine genes were identified whose expression can distinguish the myometrium origin. This suggests an underlying constitutional genetic predisposition to these somatic changes which could potentially lead to improved personalized management and treatment.
INTRODUCTION
Benign smooth muscle tumors of the uterus generally referred to as fibroids are the most common neoplasm of the female genital tract, occurring in up to 77% of women as defined by serial sectioning of uteri (1) . These uterine leiomyomata (UL) are clinically detectable in 25% of reproductive-age women, many of whom have significant morbidity often necessitating surgery to alleviate excessive menstrual bleeding, pelvic pain, urinary complaints, constipation and reproductive dysfunction (2) (3) (4) . UL are therefore the primary indication for hysterectomy, the cause for approximately one in five visits to a gynecologist, and result in expenditures exceeding 2.1 billion health-care dollars annually in the USA (5 -7).
Molecular pathways underlying UL development and growth acceleration are largely unknown and most recent discoveries have stemmed from studying recurrent cytogenetic abnormalities identified among the 40% of karyotypically abnormal UL (8, 9) . One of the most common subgroups is characterized by rearrangement of 12q14-15, typically as a t(12;14)(q14-15;q23-24), which occurs in 7.5% of all UL and 20% of karyotypically abnormal UL (10) . This high prevalence of t (12;14) and its frequent occurrence as the sole cytologically detectable chromosome abnormality suggest a primary importance for this translocation in UL tumorigenesis.
The presence of t (12;14) has been associated with larger sized UL than those with either normal karyotypes or interstitial 7q22 deletions (11) (12) (13) . In particular, a systematic study of every palpable UL in each of 96 women undergoing hysterectomy without pretreatment removed any potential bias in determining significance due to tumor sampling (i.e. selection of only larger tumors mainly as a result of myomectomy rather than hysterectomy) or due to pretreatment with gonadotropin-releasing hormone-agonists that can be used to shrink tumors prior to surgery (11) .
UL with t (12;14) have elevated expression of the high mobility group (HMGA) family member HMGA2 located at 12q14.3 (14, 15) . This architectural factor is a non-histone component of chromatin that alters DNA conformation to modulate access of transcription factors to their target genes, thereby influencing differentiation and proliferation of mesenchymal tissues (16 -19) . Consistently, transgenic mice null for Hmga2 have a 40% reduction in weight known as the pygmy phenotype (20, 21) . In fact, HMGA2 expression in both mice and humans is mainly restricted to proliferating embryonic tissues, predominantly mesenchymal derivatives including the myometrium from which UL arise, and are notably absent from differentiated adult non-proliferating counterparts (15, 22, 23) . In addition, phosphorylation of HMGA proteins by cdc2 kinase modulates their DNA binding ability in a cell cycle-dependent manner (24) . This role of HMGA2 in growth was recently extended to include an association with human height (25, 26) , which is further illustrated by an intragenic rearrangement in HMGA2 from a constitutional chromosome 12 inversion resulting in extreme multisystem overgrowth identified in the Guinness Book of World Records tallest teenager record holder (27) . In contrast to such in vivo analyses, tissue culture induction of HMGA2 expression has been shown in a variety of human tissues including myometrium and karyotypically normal UL (15) , attributed to a serum component or the weak estrogenic effect of phenol red in culture media (28) . This confounds the use of in vitro methods and necessitates direct examination of gene expression in UL tumors.
UL provide a unique in vivo model as on average six to seven independent clonal tumors occur per woman. The clonal nature of UL was confirmed by the presence of t (12;14) UL in the same uterus as UL harboring different or no chromosomal changes (1) , as well as by analysis of repeat polymorphisms in the X-linked androgen receptor and phosphoglycerokinase genes (29) (30) (31) . We have taken advantage of these circumstances for expression profiling to compare directly UL with t (12;14) to UL without t (12;14) obtained concurrently from the same uterus.
We demonstrate that such a matched (or paired) study design is a requisite to identify the molecular profile associated with the t (12;14) subgroup. This design, previously validated for the interstitial 7q22 deletion UL subgroup (32) , has not been exploited by any prior study of t (12;14) in UL. Importantly, it obviates the confounding effects of patient-to-patient variability due to divergent genotype, environment or genotype/environment interaction. In addition, the unique expression profiles we identify for myometrial samples from women with t(12;14) UL relative to those with del(7q) UL suggest an underlying genetic predisposition to these somatic alterations.
RESULTS

Screening for t(12;14) UL by fluorescence in situ hybridization and karyotyping
To identify UL with t (12;14) , interphase fluorescence in situ hybridization (FISH) or karyotype analysis was employed (Table 1) . A conservative false-positive cut-off of 15% for t (12;14) interphase FISH was established by doubling the positive rate found in normal peripheral blood lymphocytes. Probe binding to the correct target region without crosshybridization was validated on lymphocyte metaphases. Screening of 348 tumors from 140 patients identified 35 t(12;14) UL (10%). Of these 35 UL, those with matched myometrium and non-t(12;14) samples, as well as a single case found through karyotyping that was confirmed by FISH, were selected for further analysis resulting in a total of nine cases. In these t(12;14) UL, the level of mosaicism of cells not carrying the abnormality ranged from 0 to 84%. Case 3 also had a proportion of cells (25%) with another recurrent UL karyotypic abnormality, interstitial deletion of 7q22.
Identification of t(12;14)-specific UL genes
RNA from each t(12;14) UL as well as from concurrently collected non-t(12;14) UL and normal myometrium tissues from each of nine cases was hybridized on Affymetrix GeneChip Human Genome U133 Plus 2.0 oligonucleotide arrays for expression analysis. Among these cases, multiple clinical features were variable such as UL size, patient age, race and stage of menstrual cycle at the time of surgical removal ( Table 2) . To control for such variables, a direct comparison Human Molecular Genetics, 2012, Vol. 21, No. 10 2313 of the array expression data was made between tissues obtained from each individual to identify differences in expression specifically resulting from the t (12;14) . A heatmap from an unsupervised hierarchical cluster analysis of the 500 most variable genes demonstrates a tendency of myometrium tissues to cluster separately from UL samples and for the (Fig. 1A) . Separation of the myometrial samples from the overlapping UL groups can be visualized in three dimensions through principal component analysis (Fig. 1B) . These results suggest that incorporation of the myometrial array data is suited to determining genes that differentiate any UL from the normal myometrial tissue rather than identifying the t(12;14)-specific UL genes. Therefore, myometrial samples were not included in further analyses of t(12;14)-specific genes. The importance of controlling for patient-to-patient variability is illustrated by comparing the percent of genes overlapping between gene lists generated by a paired and an unpaired analysis of the t(12;14) UL and non-t(12;14) UL expression data. The two analyses had an 50% gene overlap (Fig. 1C) . Another demonstration of the need to account for variability between patients is shown by examining the distribution of P-values from paired and unpaired t-tests for a two-group comparison (Fig. 1D ). In the paired case, which considers the difference between samples of the same individual, the resultant peak on the left side of the distribution indicates that more genes with significant P-values were identified than expected from a random data set. In contrast, the unpaired analysis ignores the sample pairing and results in a distribution showing no clear evidence that genes appearing to have significant P-values from such a study design would be true positives. Based on these analyses, paired t-tests directly contrasting the t(12;14) UL and the non-t(12;14) UL from each individual were chosen to determine t(12;14)-associated genes. This resulted in a list of genes ordered by their genomewide significance levels corrected for multiple testing by the false discovery rate (Q-value) (33) . Of the 100 most significant t(12;14) UL-specific genes, those with decreased expression are reported in Table 3 and those with increased expression in Table 4 . A more extensive data set of 300 genes is provided as Supplementary Material, Table S1. The distribution of P-values for two-group comparison t-tests using a paired analysis includes a peak on the left side, indicating that more genes were found with significant P-values than expected in a random data set. In contrast, the unpaired analysis generates a decreased or nearly flat distribution, suggesting that genes with significant P-values identified by such an assessment are not likely to be true positives.
Identification of t(12;14)-specific UL genes weighted for percent mosaicism of t(12;14) cells Karyotypically abnormal UL are frequently found as mosaic tumors that include chromosomally normal cells. In contrast to previously published expression profiling studies, the impact of this biology was integrated by weighting each sample pair [t(12;14) UL and non-t(12;14) UL from the same uterus] for percent t(12;14) mosaicism of the tumor in a paired differential expression analysis: the higher the percentage of t(12;14) cells present, the more heavily weighted was that sample. The 50 most significant genes based on Q-value in this modified t(12;14) UL-specific gene list are given in Table 5 . A more expansive list of 300 genes is also presented (Supplementary Material, Table S2 ). The top eight genes from this mosaicism-weighted list, which have significant Q-values of ≤0.10, are illustrated by scatter plots ( Fig. 2A ) with details tabulated (Fig. 2B) . This demonstration of a relationship between expression and percent mosaicism suggests that weighting the samples for mosaicism level is necessary to compensate for background noise caused by the karyotypically normal cells in order to identify those genes specific to the t (12;14) . The validity of this approach is supported by the movement of HMGA2, which is known to be highly up-regulated in t(12;14) UL, to the first position on the mosaicism-weighted list from its fifth position on the nonweighted list.
Quantitative polymerase chain reaction and immunohistochemistry confirmation of elevated HMGA2 expression
In the nine cases investigated by microarray expression analysis, quantitative polymerase chain reaction (Q-PCR) confirmed that t(12;14) UL have significantly increased HMGA2 mRNA compared with matched myometrium using a Wilcoxon signed-rank test (P ¼ 0.0039). In addition, HMGA2 mRNA in t(12;14) UL relative to matched myometrium was generally equivalent among tumors with .50% t(12;14) cells, suggesting a potential saturation effect in gene expression (Supplementary Material, Fig. S1 ). Elevated HMGA2 protein was also detected in t(12;14) UL relative to matched non-t(12;14) UL in both cases for which immunohistochemistry of paraffin sections was performed (an increase of 2.25-fold in Case 4 and of 1.77-fold in Case 5).
Q-PCR confirmation of elevated CCND1 and CCND2 RNA expression and immunohistochemistry confirmation of increased CCND1 protein expression Cases 1, 4, 6, 8 and 9 for which additional RNA was available were evaluated by Q-PCR for expression of CCND1 (cyclin D1). The 2.3-fold increase in RNA expression of CCND1 in t(12;14) UL relative to matched non-t(12;14) tumors after normalization to the housekeeping gene GAPDH correlated with 
Functional significance of t(12;14)-specific UL genes
To extract biological insight from the transcriptional profile of t(12;14) UL, the 374 probe sets with P ≤ 0.005 from the t(12;14) mosaicism-weighted gene list were investigated with Ingenuity Pathways Analysis (IPA). IPA is a websupported tool based on a database of functional relationships between genes manually curated from scientific publications. There were 13 highly significant networks of dependencies generated, each involving 7 -25 genes from the t(12;14) UL-specific list. The two most significant networks ( Fig. 3A and B) are principally associated with cell proliferation and development. The other networks involving 7-20 t(12;14) UL-specific genes are generally associated with cell cycle, growth and signaling, cancer, cell and tissue morphology, nucleic acid and lipid metabolism, developmental and other disorders, and normal development pathways of multiple different systems. Among well-characterized canonical pathways, cell cycle G1/S checkpoint regulation was the most significant (P ¼ 0.0042), involving increased expression of four t(12;14) UL-specific genes: CCND1, CCND2, CCND3 and CDK6. Gene Set Enrichment Analysis (GSEA) was also employed which uses a continuum of differential expression scores for all genes rather than dividing the genes into significant versus non-significant categories (34) . Application of GSEA to the mosaicism-weighted t(12;14) UL-specific gene list identified significant enrichment (a false discovery rate of ,0.2) for eight gene sets including two associated with mitotic cell cycle (G1/S checkpoint and interphase), which is consistent with the IPA (Fig. 4) . The six other significant gene sets were primarily associated with GTPase or kinase activity, possibly indicating additional molecular pathways differentially activated between t(12;14) and non-t(12;14) UL.
Menopause or medications creating a hypogonadal state do not appear to significantly alter the t(12;14) expression analysis UL are hormonally responsive to the gonadal steroids estrogen and progesterone, and four of the nine women in this study were menopausal or on medications creating a hypogonadal state at the time of tumor collection (Table 2) . Thus, an assessment was undertaken of whether the same genes are significantly changed when only the non-menopausal/ non-medicated subset is examined. The mosaicism-weighted fold changes (log 2 scale) between the whole data set (n ¼ 9) and the non-menopausal/non-medicated subset (n ¼ 5)
showed a high Pearson's correlation (r ¼ 0.875). Further, both in total and non-menopausal/non-medicated cases, the top variable probes corresponded to HMGA2 (Supplementary Material, Fig. S2 ). As anticipated, the results favor the premise that a paired comparison of a t(12;14) UL and a non-t(12;14) UL from each woman neutralizes environmental influences such as menopausal status from significantly affecting the gene expression analysis. In addition, application of GSEA to only the non-menopause data subset confirmed the importance of the mitotic G1/S checkpoint with a false discovery rate of 0.18.
Genetic heterogeneity among UL subgroups
After combining the t(12;14) UL expression data set with the previously published del(7q) UL data set (GEO accession GSE12814) (32), the top 1000 most variable genes were selected for an unsupervised hierarchical cluster analysis with adjustment for batch effect (Fig. 5) (35) . The results substantiate the previous findings of the individual t(12;14) or del(7q) analyses where myometrium samples largely separated from the tumors while the tumors generally clustered by patient rather than by non-t(12;14)/non-del(7q) versus t(12;14)/del(7q) status. In addition, although there was not a distinct separation of t(12;14) and del(7q) tumors, the weighted t(12;14) UL-and the weighted del(7q) UL-specific gene lists were mutually exclusive (i.e., only three common genes were observed between the top 500 genes; P-value of . GSEA found eight molecular functions, including two involving the cell cycle, significantly enriched with genes which were differentially expressed between t(12;14) UL and non-t(12;14) UL based on a false discovery rate (FDR) of ,0.2. Plots of these eight molecular functions show the enrichment score (y-axis) across the genes (x-axis) sorted in the order of differential expression (upper section, each panel). Vertical bars represent genes that belong to the functional set (middle section, each panel). The leading edge gene subset is provided as a list of gene symbols (bottom section, each panel). The peak value of the enrichment score is reported as ES and the normalized value as NES. exclusivity ¼ 0.0071 using Fisher's exact test). These results indicate patient bias (constitutional genetics and/or environmental exposures) likely significantly interferes with identifying the transcriptional effects of the t(12;14) and del(7q) somatic changes, suggesting the necessity of matched sample analysis to remove this bias.
Genetic heterogeneity among myometrial samples
The myometrium samples not only segregated from the tumors, but within the myometrium group, t(12;14) patients generally clustered separately from the del(7q) patients even after batch effect correction (Fig. 5) . The ability to distinguish myometrium obtained from t(12;14) UL patients versus those with del(7q) UL was confirmed by the finding of 100% accuracy to call the tumor karyotypic abnormalities associated with each myometrium sample using a leave-one-out crossvalidation test [n ¼ 7 t(12;14) patients and n ¼ 9 del(7q) patients]. Myometrium samples excluded from this analysis were from two patients with both a t(12;14) and a del(7q) tumor (samples D5M/T3M and D10M/T6M). Nine genes were identified using the k-NN (k-nearest neighbor) method that can distinguish the myometrium origin and are illustrated with a heatmap (Fig. 6 ).
DISCUSSION
Identification of recurrent primary chromosome abnormalities in UL suggests that these tumors arise through multiple genetic pathways. One major UL cytogenetic subgroup, t(12;14)(q14-15;q23-24), has the pathogenetic target HMGA2 that is involved in multiple mesenchymal solid tumors (36, 37) . The presence of t (12;14) in UL leads to elevated expression of HMGA2 (14, 15) . Real-time PCR and immunohistochemistry in the current investigation confirmed increased HMGA2 in t(12;14) UL relative to matched non-t(12;14) UL and myometrium. Elevated HMGA2 has also been noted in many malignant tumors (38) .
In the present study, a molecular signature of t(12;14) UL was identified by directly comparing expression profiles of t(12;14) UL and non-t(12;14) UL removed concurrently from the same uterus in each of nine women. This approach is different from previously published expression studies which compare UL with normal myometrial tissue. Our data demonstrated that t(12;14) UL and non-t(12;14) UL clustered separately from myometrium, which suggests that expression profiling of myometrium does not help elucidate t(12;14) UL-specific genes. UL were also noted to generally cluster by patient rather than t(12;14) versus non-t(12;14) status, suggesting a need to control for patient variability caused by genetic and environmental factors such as menstrual cycle status. Therefore, a paired comparison of t(12;14) UL to non-t(12;14) UL to increase specificity was used to develop a molecular signature of the t(12;14) abnormality. In addition, data were further refined through weighting based on the percent of abnormal t(12;14) cells in each neoplasm to account for the mosaic nature of UL.
The need for a paired design is illustrated by the finding that menopause, the absence of steroid hormones which are a known environmental influence on UL growth, does not appear to significantly affect the t(12;14) gene list in this study. This was demonstrated by a significant correlation in gene expression between the non-menopausal case subset and the whole data set, including HMGA2 as the most highly expressed transcript in both groups.
To study further the genetic expression of t(12;14) UL, this data set including the myometrium was combined with that of a previously published 7q22 deletion cytogenetic subgroup (32) , and an unsupervised hierarchical cluster analysis was performed. The tumors tended to cluster by patient rather than by the presence or absence of the cytogenetic abnormality. The t(12;14) UL were also not clearly distinguishable from the del(7q) UL. This suggests that patient variability due to constitutional genetics and/or environment has a predominant effect, and therefore, a paired analysis is likely required to determine t(12;14) UL-specific genes. This patient variability effect is so strong that in a single case with independent del(7q) and t(12;14) UL [Case 6 in Table 1 and Case 10 in (32)], it was found that those tumors clustered together along with the non-del(7q)/non-t(12;14) UL from the same woman (D10, T6, D10N/T6N in Fig. 5 ). In addition, the single tumor that is a low-level mosaic for both del(7q) and t (12;14) [Case 3 in Table 1 and Case 5 in (32)] presented within the myometrium branch (D5/T3, D5N/T3N, D5M/ T3M in Fig. 5 ), suggesting the genetic effects of both cytogenetic abnormalities are diluted by the mosaicism with each other and with normal cells.
A second result of this analysis was the finding that within the myometrium cluster, t(12;14) patients generally gathered separately from the del(7q) patients. Nine genes were identified that could predict whether a myometrium sample came from a woman with a t(12;14) UL versus a woman with a del(7q) UL. This suggests that there are different constitutional genetic predisposition alleles in women for these specific cytogenetic subgroups. Alternative potential mechanisms affecting myometrium expression can include a paracrine effect of UL with different cytogenetic abnormalities on adjacent myometrium or unappreciated microscopic UL in one or more of the myometrial samples. Precedent for general UL genetic predisposition was established by a genome-wide association study in which three loci were significantly associated with UL susceptibility (39) . Further investigations are required to determine whether genetic predilection to UL formation in general is related to the potential constitutional predisposition to specific cytogenetic abnormalities in UL.
Among the nine genes that can differentiate between the myometrium of t(12;14) and del(7q) patients, PLAG1 (pleomorphic adenoma gene 1) is significant as this proto-oncogene is ectopically overexpressed through recurrent translocations or amplifications in multiple neoplasms. Pleomorphic adenoma of the salivary gland is one such tumor; this benign growth is of particular interest as a subset harbor HMGA2 rearrangement similar to the t(12;14) subgroup of UL (40) . Further, like HMGA2, the expression of PLAG1 is usually restricted to fetal development (41) . PLAG1 has also been shown to drive cell proliferation and oncogenic transformation, likely through its known mitogenic target genes such as IGF2 (42, 43) . In fact, PLAG1 increases proliferation by inducing G1/S transition in hematopoietic progenitors in cooperation with CBFB/MYH11 fusion (44) and its disruption in mice results in growth retardation (41) . These roles are interesting to consider in relation to PLAG1 expression in the myometrium, and the question remains whether there is any relationship between PLAG1 and HMGA2 in pleomorphic adenomas or other tumors such as UL.
Another gene of interest in the myometrial differential data set, PRL (prolactin), induces phosphorylation of mitogenactivated protein (MAP) kinase and DNA synthesis in UL-derived smooth muscle cells (45) . This suggests that PRL promotes UL cell proliferation via the MAP kinase cascade. Myometrial and UL cells were further shown to express the PRL receptor and to have a significant decrease in cell number in vitro after treatment with anti-PRL antibody (46) . Therefore, even a modest overproduction of the stimulatory growth factor PRL in the myometrium could result through an autocrine mechanism in sustained, self-stimulated proliferation, predisposing to tumor formation.
Other genes among the nine that are of potential relevance include MEST, CAPN6 and BCL11A due to their known neoplastic associations. MEST (mesoderm-specific transcript) is overexpressed in UL relative to myometrium across multiple Figure 6 . Nine genes distinguish the myometrial origin from t(12;14) UL or del(7q) UL patients. A heatmap showing the expression signature of these nine genes in the myometrium from each of seven women with t(12;14) UL and nine women with del(7q) UL. The myometrium from two patients were excluded due to the presence of both a t(12;14) and a del(7q) tumor (samples D5M/T3M and D10M/T6M).
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Human Molecular Genetics, 2012, Vol. 21, No. 10 expression array studies (47) and is also involved in proliferation as mice lacking MEST demonstrate growth retardation (48) . CAPN6 (calpain 6) is also overexpressed in UL relative to myometrium (49) and supports tumorigenesis through apoptosis inhibition and angiogenesis promotion (50) . BCL11A (B-cell lymphoma/leukemia 11A) codes for a proto-oncogene transcription factor which is rearranged or amplified in a variety of B-cell malignancies (51) . The myometrium of the del(7q) and t(12;14) UL cytogenetic subgroups not only differ, but in contrast to the expression profile of del(7q) (32), the mosaicism-weighted t(12;14) UL-specific gene list suggests that cell cycle regulation is of primary importance. Application of IPA to the significant probe sets (P ≤ 0.005) indicates that the top networks are principally associated with cell proliferation and development while the most-related canonical pathway is G1/S checkpoint regulation. Consistently, application of another functional analysis method, GSEA, showed significant enrichment for mitotic cell cycle function, particularly G1/S transition and interphase. Interestingly, when GSEA analysis was applied to only the subset of women who were non-menopausal, the significance of the mitotic G1/S transition function remained.
During the G1 phase of the cell cycle, D-type cyclins accumulate in response to growth signals and activate their associated cyclin-dependent kinases (CDKs), promoting progression through the restriction point to achieve S phase commitment and mitogen independence. In t(12;14) UL, the genes significantly up-regulated include multiple D-type cyclins (CCND1, CCND2, CCND3) and a CDK (CDK6). Overexpression of CDK6 or CCND1 has been shown to shorten the G1 phase and accelerate the G1/S transition (52, 53) . In addition, increased CDK6 expression was observed in squamous cell carcinomas, gliomas and neuroblastomas while CCND1 expression is characteristically elevated in multiple primary human tumors and cell lines (54) (55) (56) (57) .
Additional support for a relationship between t(12;14) and the cell cycle is shown by the marked growth advantage of t(12;14) UL, which was found in a systematic study of all palpable UL from hysterectomy specimens to be significantly larger in size than those with either interstitial 7q22 deletions or normal karyotypes (11) . This may be directly related to increased expression of HMGA2, which has been identified as a delayed early response gene in multiple cell types (58 -61) . Since delayed early response genes normally promote progression to S phase in response to growth factors, UL cells with up-regulation of HMGA2 due to t(12;14) may bypass the need for mitogen stimulation.
This connection between HMGA2 and the cell cycle is also shown by insertional mutagenesis of HMGA2 in mice which have significantly reduced body size as a result of widespread mesenchymal tissues growth restriction (21) . A gene directly regulated by HMGA2 and known to have decreased expression in these pygmy mice is insulin-like growth factor II mRNAbinding protein 2 (62, 63) . In the current study, IMP2 (also known as IGF2BP2) is number 43 on the mosaicism-weighted t(12;14) UL-specific gene list with a significant 6.2-fold increase in expression relative to non-t(12;14) UL (P ¼ 0.00039). IMP2 encodes a mRNA-binding protein involved in regulating post-transcriptional processes, including influencing the major fetal period growth factor IGF-II (64) . IMP2 may therefore function as an effector through which HMGA2 contributes to growth in t(12;14) UL.
HMGA2 or other t(12;14)-associated genes may also potentially contribute to an injury-like response in UL as is known to occur during normal menstruation when increased uterine vasoconstrictive substances induce myometrial cell hypoxia (65) . Decreased oxygen levels activate hypoxia-inducible factors (HIFs) which in turn induce transcription of genes involved in many functions including angiogenesis and cell survival (66) . HIF1A is key in the initial adaptation of cells to an oxygen-poor environment, but recent data suggest that HIF3A takes over in maintaining long-term response to hypoxia (67) . In the current study, HIF3A is a significant t(12;14) UL-specific gene, at number 24 with 2.4-fold increased expression (P ¼ 0.00039) as well as being present four additional times in the top 437 probes with an overall average fold-change of 2.1 on the mosaicism-weighted gene list. IPA indicated HIF3A as a gene involved in the second most significant network. HIF3A may not only have a tumorigenic function but, as larger tumors are prone to hypoxia at their core and t(12;14) UL are known to generally be larger, t(12;14)-induced expression of HIF3A may allow UL with this translocation to remain viable during hypoxia-inducing rapid growth.
In conclusion, this study provides an expression profile of the t(12;14) cytogenetic subgroup of UL. The unique design employed to target t(12;14) UL-specific genes included a paired comparison to non-t(12;14) UL from the same women and weighting of the data for percent of t (12;14) cells to account for mosaicism with normal cells. This paired strategy was demonstrated to be required to remove the significant impact of patient variability. The resultant gene list with the known t(12;14)-associated gene HMGA2 as the most significant gene strongly implicates the importance in t(12;14) UL of the G1 -S cell cycle checkpoint. By examining expression profiles of morphologic variants and recurrent cytogenetic subgroups of UL, it is becoming clear that UL is not a single disease. In fact, analysis of myometrium from t (12;14) and del(7q) UL cases suggests distinct constitutional genetic predisposition for these somatic changes. Recognizing this genetic heterogeneity and establishing genetic profiles of the different entities are taking the first steps toward understanding the implications of how genetic variability impacts disease occurrence, severity and recurrence, particularly as less invasive uterus-sparing procedures are becoming the standard of care.
MATERIALS AND METHODS
Clinical material
For each woman, the total number of tumors present were counted and tissue was obtained from the myometrium and a minimum of three UL (as in Cases 1 -3) or up to five UL when available (as in Cases 4 -9), selecting the tumor with the largest diameter first and others in a descending size order. All collected tumors were then screened for t(12;14)(q14-15;q23- 24) and del(7)(q22q32) using GTG-banded karyotyping according to established protocols (9) or FISH. Selection of cases for further studies required Human Molecular Genetics, 2012, Vol. 21, No. 10the t(12;14) UL had matched myometrium and non-t(12;14) UL samples acquired and screened concurrently with the karyotypically abnormal tumor. Two UL with t(12;14) (Cases 1 and 2) and one UL that was mosaic for both t (12;14) and del(7q) (Case 3) were obtained from surgical specimens at Brigham and Women's Hospital (BWH) through a Partners HealthCare IRB-approved protocol between 1990 and 2004. Six UL with t(12;14) (Cases 4 -9) were identified from an IRB-approved tissue bank of over 100 consented, premenopausal, 25-to 50-year-old women who underwent myomectomy or hysterectomy at BWH between 2003 and 2007. Diagnosis of UL was confirmed through medical record review. Participants consented for the tissue bank also completed detailed epidemiological questionnaires surveying clinical, reproductive, sexual, dietary and family history. Each case was grossly confirmed to be a UL or myometrial specimen, and when possible, hematoxylin-and eosin-stained tissue sections underwent pathologic evaluation (Table 1) .
Fluorescence in situ hybridization
End-sequenced and FISH-verified bacterial artificial chromosomes (68) were selected using the University of California Santa Cruz Biotechnology Genome Browser and Database (http://genome.ucsc.edu) (69) and then obtained from the RP11 library (BACPAC Resource Center at the Children's Hospital Oakland Research Institute, Oakland, CA, USA) or the CTD library (Invitrogen). DNA was isolated from bacterial cultures following a standard protocol consisting of alkaline lysis, neutralization and ethanol precipitation.
UL with t(12;14)(q14-15;q23-24) were identified by the presence of a fusion signal of probes RP11-185D13 located at 12q14.3 and CTD-3225F7 at 14q24 by interphase FISH on nuclei from fresh fixed cell pellets as described previously (70) . A total of 100 interphase nuclei were scored for each specimen. The probe set was validated on both normal metaphases from peripheral blood lymphocytes and on interphase nuclei from karyotype-confirmed t(12;14) UL.
Immunohistochemistry for HMGA2
Detection of HMGA2 protein in formalin-fixed, paraffin-embedded t(12;14) UL and matched non-t(12;14) UL tissue sections for Cases 4 and 5 involved pressure cooker heat-induced antigen retrieval for 2 min in citrate buffer followed by a 20 min cool down, a 5 min 0.05 M Tris/Tween 20 wash, a 5 min peroxidase block (Dako) and a 5 min Tris incubation. A 1:2000 dilution of a primary polyclonal anti-HMGA2 antibody (Biocheck, Inc.) was used for 40 min. The Envision Plus detection system (Dako) was then applied, including a 30 min incubation with goat anti-rabbit immunoglobulin conjugated to a peroxidase-labeled polymer [horseradish peroxidase (HRP)] followed by a 5 min exposure to the substrate diaminobenzidine (DAB) to produce a brown precipitate visible by microscopy. Hematoxylin was used as the counterstain. All steps were performed at room temperature unless otherwise noted. HMGA2 protein expression (brown) versus background (blue) staining was evaluated using a semi-automated image analysis system (ACISII, Chromavision) (71) , and the results of two separate sections from each sample were averaged. HMGA2 staining for each t(12;14) UL sample is expressed as a fold change compared with a matched non-t(12;14) UL from the same patient.
Immunohistochemistry for CCND1
Immunohistochemistry to detect CCND1 protein in t(12;14) UL and matched non-t(12;14) UL for Cases 4 and 5 was performed in the Specialized Histology Core of the Dana-Farber/ Harvard Cancer Center. Five-micron formalin-fixed, paraffin-embedded tissue sections were deparaffinized and subjected to antigen retrieval in a pressure cooker for 2 min in citrate buffer. After washing, the endogenous peroxidase activity was quenched (Peroxidase block, Dako) for 20 min and slides were incubated with rabbit polyclonal anti-cyclin D1 antibody (1:40, Thermo Fisher Scientific) for 60 min. Following washing, the Envision Plus detection system (Dako) was applied, including a 30 min incubation with goat anti-rabbit immunoglobulin conjugated to a peroxidase-labeled polymer (HRP) followed by a 5 min exposure to the substrate diaminobenzidine (DAB) to produce a brown precipitate visible by microscopy. Hematoxylin was used as the counterstain. All steps subsequent to antigen retrieval were performed at room temperature. CCND1 protein expression (brown) versus background (blue) staining was evaluated by dividing each stained tumor into four quadrants, visually assessing 20 nuclei in each quadrant and then averaging the data from the four quadrants. The results of two separate sections from each tumor were also averaged. CCND1 staining for each t(12;14) UL sample is expressed as fold change compared with a non-t(12;14) UL from the same patient.
RNA isolation
A portion of each of the myometrial, non-t(12;14) UL and t(12;14) UL tissues was frozen in liquid nitrogen immediately after surgical removal or placed directly into RNAlater solution (QIAGEN). RNA was isolated using the RNeasy Fibrous Tissue kit with a provided standard protocol (QIAGEN) and assessed for purity and quantity on a Nanodrop spectrophotometer (Thermo Scientific).
Q-PCR for HMGA2
Quantitative PCR was performed as previously described (14) using the standard curve method and normalizing the level of HMGA2 in each tissue to that of GAPDH.
Q-PCR for CCND1 and CCND2
Total RNA from the t(12;14) and non-t(12;14) UL from each of five women (Cases 1, 4, 6, 8 and 9) was examined for CCND1 and CCND2 gene expression. PCR was performed on the ABI PRISM 7900HT Sequence Detection System in a 384-well format. TaqMan Universal PCR MasterMix and a pre-designed and optimized Taqman Gene Expression Assay for quantitation of human CCND1 or CCND2 RNA (Applied Biosystems) were used according to the manufacturer's instructions. Each RNA was run in quadruplicate and the C t (cycle threshold) values of these replicates were averaged and then normalized by subtracting the C t value of the co-amplified internal control housekeeping gene GAPDH for a DC t value. Data analysis used the comparative C t method where the DC t of a non-t(12;14) UL was used as a calibrator reference and subtracted from the DC t of the corresponding t(12;14) UL to yield a DDC t value. This was then converted into a fold-change relative to one using the following formula: CCND1 or CCND2 expression ¼ 2 (−DDC t ) . For each gene, this number was then averaged across the five samples.
Transcriptional profiling
Total RNA isolated from the myometrial, non-t(12;14) UL and t(12;14) UL tissues from each of nine cases was assessed for quality by RNA Nano LabChip analysis on an Agilent Bioanalyzer 2100 and then applied to GeneChip Human Genome U133 Plus 2.0 oligonucleotide expression microarrays (Affymetrix). Standard protocols as described in the Affymetrix GeneChip Expression Analysis Technical Manual revision 5 were employed at the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG). Briefly, 5 mg of total RNA template from each sample was reverse-transcribed into cDNA using oligo-dT primer containing T7 RNA polymerase-binding sites using the GeneChip Expression 3
′ -Amplification Reagents One-Cycle cDNA Synthesis kit with subsequent purification of the doublestranded product with Affymetrix GeneChip Cleanup Module (Affymetrix). In vitro transcription to produce complementary RNA (cRNA) using T7 Polymerase and biotinylated dUTP and dCTP was performed with the GeneChip Expression Amplification Reagents kit (Affymetrix) and the biotin-labeled product quantitated on a UV plate reader (Bio-Tek). Following purification and fragmentation to reduce secondary structure, hybridization occurred overnight at 458C in a Model 640 hybridization chamber to expression microarrays containing over 54 000 oligonucleotide probe sets representing more than 47 000 transcripts and 38 500 well-characterized genes. Arrays were washed using a Model 450 Fluidics station with GeneChip Operating Software (Affymetrix) and then scanned by the GeneChip Model 3000 7G. Array images were inspected visually for experimental artifacts and various quality measurements such as present versus absent calls and RNA degradation were examined to verify the quality of the data. Probe set expression values were calculated by GeneChip software using the MAS 5.0 algorithm. Probe sets with fewer than five present calls among the t(12;14), non-t(12;14) and myometrium arrays were excluded. Paired differential expression analysis (not accounting for percent mosaicism) between t(12;14) and non-t(12;14) UL was computed using paired t-tests in which tissue samples were analyzed as matched pairs based on patient status. Mosaicism-weighted paired differential expression analysis was implemented in the Bioconductor (72) package limma (73) by fitting a linear model with weights equal to the percent mosaicism. All differential expression analyses were corrected for multiple testing using the false discovery rate (Q-value). Data analysis was carried out in the statistical language R (http://www.r-project.org).
Expression data were deposited at the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/); the series entry number is GSE18096 and the specific accession identifiers are listed in Table 1 .
Ingenuity Pathways Analysis and Gene Set Enrichment Analysis
Functional analysis of the 374 probe sets with a P-value of ≤0.005 from the t(12;14) UL-specific gene list weighted for t (12;14) cell mosaicism was performed using IPA (Ingenuity Systems, www.Ingenuity.com). Networks were generated to look for interactions of the t(12;14) UL-specific genes with others based on the literature as curated in the Ingenuity Pathway Knowledge Base. Fisher's exact test was used to calculate statistical significance of a network, which is the probability of observing the number of genes from the t(12;14) UL-specific gene list given the number of genes belonging to the network. The network score is calculated by 2log 10 (P-value). Networks with a score of 8 -46 were highly significant and included 7-25 genes from the t(12;14) UL-specific list.
For the GSEA method, 700 gene ontology (GO) functional annotations that have ≥20 genes and ≤500 genes were collected from MSigDB (http://www.broadinstitute.org/gsea/m sigdb/index.jsp; MSigDB c5 GO category). The extent of enrichment (enrichment score) was calculated for the individual GO categories using the weighted Kolmogorov-Smirnov statistic as described previously (34) . The significance was determined based on 1000 gene permutation tests and adjusted for multiple tests.
Analysis of merged del(7q) UL and t(12;14) UL data sets
The t(12;14) UL expression data and the published del(7q) UL data (GEO accession GSE12814) (32) , which used the same array platform (GeneChip Human Genome U133 Plus 2.0), were merged. The combined expression profile was processed using ComBat (35) to adjust for batch effect. Agglomerative hierarchical clustering was performed on the 1000 top variable genes using Pearson's correlation as distance with average linkage. To test the hypothesis that myometrium from t(12;14) versus del(7q) patients can be distinguished based on expression profiles, the k-NN method was employed (74) . In leave-one-out cross-validation tests for 16 predictions of seven t(12;14) and nine del(7q) myometrium, the prediction accuracy of 100% was achieved with a class predictor size of 20 genes. We report nine genes (PLP1, MEST, PCDH20, SLC26A7, BCL11A, PRL, LOC727770, CAPN6 and PLAG1) that were observed in all 16 sets of class predictors.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online. quantitation of the resulting stained slides, Karen T.Cuenco for discussion of a data analysis method for the real-time PCR results and the Dana Farber Harvard Cancer Center Specialized Histology Core (P30 CA006516) for CCND1 immunohistochemistry.
